Effects of HIIT vs. TRE on Type 2 Diabetes Risk
Differential Effects of HIIT vs. TRE on Type 2 Diabetes Risk in Youth and Younger Adults
1 other identifier
interventional
40
1 country
1
Brief Summary
The primary aim of this randomized controlled trial is to examine the effects of a 4-week high-intensity interval training (HIIT) and time-restricted eating (TRE) intervention on cardiometabolic biomarkers in adolescents and young adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Mar 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 15, 2024
CompletedFirst Submitted
Initial submission to the registry
April 28, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2025
CompletedFirst Posted
Study publicly available on registry
October 10, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2025
CompletedOctober 10, 2025
October 1, 2025
1.5 years
April 28, 2025
October 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (17)
Weight (kg)
Weight is measured in kilograms (kg) using a calibrated digital scale.
Baseline and after 4 weeks of intervention
Height (cm)
Height is measured in centimeters (cm) using a wall-mounted stadiometer.
Baseline and after 4 weeks of intervention
Body Mass Index (BMI)
Weight and height will be combined to report BMI in kg/m².
Baseline and after 4 weeks of intervention
Waist Circumference and Hip Circumference
Waist and hip circumferences are measured while participants stand straight with their arms extended outward. A non-elastic tape measure is wrapped around the waist and hip, and measurements are taken to the nearest centimeter (cm).
Baseline and after 4 weeks of intervention
Blood Lipid Profile
Blood lipid profile, including total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), and fasting glucose (FG) are measured in milligrams per deciliter (mg/dL) using the Cholestech LDX Analyzer. Blood samples are obtained via fingerstick, with the first drop wiped away and the second drop collected for analysis. Participants stand or sit comfortably during collection. After blood collection, the site is cleaned and covered with gauze and a bandage as needed. This procedure is minimally invasive and typically causes little discomfort.
Baseline and after 4 weeks of intervention
Blood Pressure
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) are measured in millimeters of mercury (mmHg), and resting heart rate (RHR) is measured in beats per minute (bpm) using an automated blood pressure monitor. Participants sit quietly for five minutes with minimal movement prior to measurement. A cuff is placed on the right upper arm (bicep area), and the monitor initiates inflation, deflation, and reinflation cycles. Participants are instructed not to move during the measurement process. All equipment is disinfected before and after each use with antiviral, antibacterial, and antifungal disposable wipes by a researcher wearing gloves.
Baseline and after 4 weeks of intervention
Carotid-Femoral Pulse Wave Velocity
Carotid-femoral pulse wave velocity (PWV), a preclinical marker of cardiovascular disease (CVD), is measured in meters per second (m/s) using applanation tonometry (SphygmoCor, AtCor Medical). Participants are positioned supine on a padded exam table after resting quietly for approximately five minutes. Brachial blood pressure is measured in millimeters of mercury (mmHg) using an automated cuff device. Pressure waveforms are recorded at the carotid artery (neck) and femoral artery (upper leg) using a handheld tonometer. The time delay between carotid and femoral pulse waves is used to calculate PWV, an indicator of arterial stiffness. The procedure is non-invasive and typically requires approximately five minutes to complete.
Baseline and after 4 weeks of intervention
Glucose (mg/dL)
After a 10- to 12-hour overnight fast, participants undergo a 2-hour oral glucose tolerance test (OGTT) at the Clinical Research Unit, SUNY Upstate Medical University. Venous blood samples are collected at -15, 0, 30, 60, 90, and 120 minutes relative to glucose ingestion. At time 0 minutes, participants consume a commercially prepared standard 75-gram glucose solution; youth participants receive 1.75 grams of glucose per kilogram of body weight, not exceeding 75 grams total. After the final blood collection at 120 minutes, participants are provided a snack and continue their study visit. Blood is collected in pre-chilled aprotinin/EDTA tubes and processed for analysis of glucose (mg/dL).
Baseline and after 4 weeks of intervention
Insulin (μIU/mL)
After a 10- to 12-hour overnight fast, participants undergo a 2-hour oral glucose tolerance test (OGTT) at the Clinical Research Unit, SUNY Upstate Medical University. Venous blood samples are collected at -15, 0, 30, 60, 90, and 120 minutes relative to glucose ingestion. At time 0 minutes, participants consume a commercially prepared standard 75-gram glucose solution; youth participants receive 1.75 grams of glucose per kilogram of body weight, not exceeding 75 grams total. After the final blood collection at 120 minutes, participants are provided a snack and continue their study visit. Blood is collected in pre-chilled aprotinin/EDTA tubes and processed for analysis of insulin (μIU/mL).
Baseline and after 4 weeks of intervention
C-peptide (ng/mL)
After a 10- to 12-hour overnight fast, participants undergo a 2-hour oral glucose tolerance test (OGTT) at the Clinical Research Unit, SUNY Upstate Medical University. Venous blood samples are collected at -15, 0, 30, 60, 90, and 120 minutes relative to glucose ingestion. At time 0 minutes, participants consume a commercially prepared standard 75-gram glucose solution; youth participants receive 1.75 grams of glucose per kilogram of body weight, not exceeding 75 grams total. After the final blood collection at 120 minutes, participants are provided a snack and continue their study visit. Blood is collected in pre-chilled aprotinin/EDTA tubes and processed for analysis of C-peptide (ng/mL).
Baseline and after 4 weeks of intervention
Total glucagon-like peptide-1 (GLP-1) (pmol/L)
After a 10- to 12-hour overnight fast, participants undergo a 2-hour oral glucose tolerance test (OGTT) at the Clinical Research Unit, SUNY Upstate Medical University. Venous blood samples are collected at -15, 0, 30, 60, 90, and 120 minutes relative to glucose ingestion. At time 0 minutes, participants consume a commercially prepared standard 75-gram glucose solution; youth participants receive 1.75 grams of glucose per kilogram of body weight, not exceeding 75 grams total. After the final blood collection at 120 minutes, participants are provided a snack and continue their study visit. Blood is collected in pre-chilled aprotinin/EDTA tubes and processed for analysis of total glucagon-like peptide-1 (GLP-1) (pmol/L).
Baseline and after 4 weeks of intervention
Glucose-dependent insulinotropic polypeptide (GIP) (pg/mL)
After a 10- to 12-hour overnight fast, participants undergo a 2-hour oral glucose tolerance test (OGTT) at the Clinical Research Unit, SUNY Upstate Medical University. Venous blood samples are collected at -15, 0, 30, 60, 90, and 120 minutes relative to glucose ingestion. At time 0 minutes, participants consume a commercially prepared standard 75-gram glucose solution; youth participants receive 1.75 grams of glucose per kilogram of body weight, not exceeding 75 grams total. After the final blood collection at 120 minutes, participants are provided a snack and continue their study visit. Blood is collected in pre-chilled aprotinin/EDTA tubes and processed for analysis of glucose-dependent insulinotropic polypeptide (GIP) (pg/mL).
Baseline and after 4 weeks of intervention
Leptin (ng/mL)
After a 10- to 12-hour overnight fast, participants undergo a 2-hour oral glucose tolerance test (OGTT) at the Clinical Research Unit, SUNY Upstate Medical University. Venous blood samples are collected at -15, 0, 30, 60, 90, and 120 minutes relative to glucose ingestion. At time 0 minutes, participants consume a commercially prepared standard 75-gram glucose solution; youth participants receive 1.75 grams of glucose per kilogram of body weight, not exceeding 75 grams total. After the final blood collection at 120 minutes, participants are provided a snack and continue their study visit. Blood is collected in pre-chilled aprotinin/EDTA tubes and processed for analysis of leptin (ng/mL).
Baseline and after 4 weeks of intervention
Adiponectin (μg/mL)
After a 10- to 12-hour overnight fast, participants undergo a 2-hour oral glucose tolerance test (OGTT) at the Clinical Research Unit, SUNY Upstate Medical University. Venous blood samples are collected at -15, 0, 30, 60, 90, and 120 minutes relative to glucose ingestion. At time 0 minutes, participants consume a commercially prepared standard 75-gram glucose solution; youth participants receive 1.75 grams of glucose per kilogram of body weight, not exceeding 75 grams total. After the final blood collection at 120 minutes, participants are provided a snack and continue their study visit. Blood is collected in pre-chilled aprotinin/EDTA tubes and processed for analysis of adiponectin (μg/mL).
Time Frame: Baseline and after 4 weeks of intervention
Ghrelin (pg/mL)
After a 10- to 12-hour overnight fast, participants undergo a 2-hour oral glucose tolerance test (OGTT) at the Clinical Research Unit, SUNY Upstate Medical University. Venous blood samples are collected at -15, 0, 30, 60, 90, and 120 minutes relative to glucose ingestion. At time 0 minutes, participants consume a commercially prepared standard 75-gram glucose solution; youth participants receive 1.75 grams of glucose per kilogram of body weight, not exceeding 75 grams total. After the final blood collection at 120 minutes, participants are provided a snack and continue their study visit. Blood is collected in pre-chilled aprotinin/EDTA tubes and processed for analysis of ghrelin (pg/mL).
Baseline and after 4 weeks of intervention
C-reactive protein (CRP) (mg/L)
After a 10- to 12-hour overnight fast, participants undergo a 2-hour oral glucose tolerance test (OGTT) at the Clinical Research Unit, SUNY Upstate Medical University. Venous blood samples are collected at -15, 0, 30, 60, 90, and 120 minutes relative to glucose ingestion. At time 0 minutes, participants consume a commercially prepared standard 75-gram glucose solution; youth participants receive 1.75 grams of glucose per kilogram of body weight, not exceeding 75 grams total. After the final blood collection at 120 minutes, participants are provided a snack and continue their study visit. Blood is collected in pre-chilled aprotinin/EDTA tubes and processed for analysis of C-reactive protein (CRP) (mg/L).
Baseline and after 4 weeks of intervention
Interleukin-6 (IL-6) (pg/mL)
After a 10- to 12-hour overnight fast, participants undergo a 2-hour oral glucose tolerance test (OGTT) at the Clinical Research Unit, SUNY Upstate Medical University. Venous blood samples are collected at -15, 0, 30, 60, 90, and 120 minutes relative to glucose ingestion. At time 0 minutes, participants consume a commercially prepared standard 75-gram glucose solution; youth participants receive 1.75 grams of glucose per kilogram of body weight, not exceeding 75 grams total. After the final blood collection at 120 minutes, participants are provided a snack and continue their study visit. Blood is collected in pre-chilled aprotinin/EDTA tubes and processed for analysis of
Baseline and after 4 weeks of intervention
Study Arms (3)
High-intensity interval training
EXPERIMENTALHIIT: The 4-week HIIT intervention will use a stationary bicycle performed 3 times/week (a total of 12 sessions over the 4-week), performing at the CRL. All participants will perform a 20-minute HIIT protocol (20 repetitions of 10-seconds work time followed by 50-seconds resting/active recovery for the first two weeks, and 10 repetitions of 20-seconds work time followed by 100-seonds resting/active recovery for the rest of two weeks; targeted 90% HRmax) after 5-minute warm-up (10% HRmax). The supervisor (PI: Joon Young Kim and/or Graduate researcher: Wonhee Cho) will provide encouragement and supervision for exercise adherence. Heart rate (Polar, Polar Electro Oy, Kempele, Finland) and rating of perceived exertion (RPE; detail described in the questionnaire section) will be recorded.
Time-restricted eating
EXPERIMENTALParticipants randomized into the TRE group will be instructed to consume all their calories within a 10-hour period. We will instruct participants that they can choose their time-window (early TRE \[7am - 5pm\] or late TRE \[1pm - 11pm\]), but it must remain constant for the duration of the study. Further, we will give no restrictions on the type of foods and/or the quantities individuals can consume. We will ask individuals to maintain their diet for the duration of the study. Participants will be given clear instructions on their diet and how to use the "MyFitnessPal" application. Participants will have their total daily energy requirement calculated using the following formula (Basal metabolic rate \[BMR\] x activity level) and will be told to eat that amount within their allotted time window. BMR will be calculated when participants have their body composition taken by the InBody. Participants will be told to start their 4-week diet the following day after visit.
Control Group
NO INTERVENTIONParticipants randomized into the control group will be told to maintain their daily lifestyle and dietary habits for the duration of the four weeks.
Interventions
The 4-week HIIT intervention will use a stationary bicycle performed 3 times/week (a total of 12 sessions over the 4-week), performing at the CRL. All participants will perform a 20-minute HIIT protocol (20 repetitions of 10-seconds work time followed by 50-seconds resting/active recovery for the first two weeks, and 10 repetitions of 20-seconds work time followed by 100-seonds resting/active recovery for the rest of two weeks; targeted 90% HRmax) after 5-minute warm-up (10% HRmax). The supervisor (PI: Joon Young Kim and/or Graduate researcher: Wonhee Cho) will provide encouragement and supervision for exercise adherence. Heart rate (Polar, Polar Electro Oy, Kempele, Finland) and rating of perceived exertion (RPE; detail described in the questionnaire section) will be recorded.
Participants randomized into the TRE group will be instructed to consume all their calories within a 10-hour period. We will instruct participants that they can choose their time-window (early TRE \[7am - 5pm\] or late TRE \[1pm - 11pm\]), but it must remain constant for the duration of the study. Further, we will give no restrictions on the type of foods and/or the quantities individuals can consume. We will ask individuals to maintain their diet for the duration of the study. Participants will be given clear instructions on their diet and how to use the "MyFitnessPal" application. Participants will have their total daily energy requirement calculated using the following formula (Basal metabolic rate \[BMR\] x activity level) and will be told to eat that amount within their allotted time window. BMR will be calculated when participants have their body composition taken by the InBody. Participants will be told to start their 4-week diet the following day after visit.
Eligibility Criteria
You may qualify if:
- Adolescents (age 14-17 years old with sex- and race-specific BMI percentile ≥85th) and young adults with overweight and obesity (age 18 to 30 years old with BMI ≥25 kg/m2)
You may not qualify if:
- Chronic medical conditions: heart disease, arrhythmias, diabetes, thyroid disease, bleeding disorder, history of pulmonary disease, hypertension, hepatorenal disease, musculoskeletal disorder, neuromuscular/neurological disease, autoimmune disease, cancer, peptic ulcers, anemia, or chronic infection (HIV).
- Have taken any heart, pulmonary, thyroid, anti-hyperlipidemic, hypoglycemic, anti- hypertensive, endocrinologic (e.g., thyroid, insulin, etc.), emotional/psychotropic (e.g., Prednisone, Ritalin, Adderall), neuromuscular/neurological, or androgenic medications (anabolic steroids).
- Have a pacemaker.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Syracuse University
Syracuse, New York, 13244, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 28, 2025
First Posted
October 10, 2025
Study Start
March 15, 2024
Primary Completion
September 30, 2025
Study Completion
December 30, 2025
Last Updated
October 10, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will not share